Trial · NCT04702737
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Who Experienced One or More Treatment-emergent Adverse Events (TEAEs) | Tarlatamab Dose Expansion | 40 | Participants | ||
| Number of Participants Who Experienced One or More Treatment-related Adverse Events (TRAE) | Tarlatamab Dose Expansion | 40 | Participants | ||
| Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) | Tarlatamab Dose Expansion | 1 | Participants | ||
| Objective Response Rate (ORR) | Tarlatamab Dose Expansion | 12.0 | 95% Confidence Interval 2.5 to 31.2 | percentage of participants | |
| Duration of Response (DOR) | Tarlatamab Dose Expansion | NA | 95% Confidence Interval NA to NA | months | |
| Radiographic Progression-free Survival (PFS) | Tarlatamab Dose Expansion | 2.1 | 95% Confidence Interval 1.8 to 3.8 | months | |
| Overall Survival (OS) | Tarlatamab Dose Expansion | 7.9 | 95% Confidence Interval 4.4 to 13.2 | months | |
| Disease Control Rate (DCR) | Tarlatamab Dose Expansion | 36.0 | 95% Confidence Interval 18.0 to 57.5 | percentage of participants | |
| Maximum Serum Concentration (Cmax) of Tarlatamab | Tarlatamab Dose Expansion | Cycle 2 Day 1 | 31.1 | Geometric Coefficient of Variation 26 | μg/mL |
| Maximum Serum Concentration (Cmax) of Tarlatamab | Tarlatamab Dose Expansion | Cycle 2 Day 15 | 31.7 | Geometric Coefficient of Variation 19 | μg/mL |
| Tarlatamab Concentration at the End of a Dosing Interval or Before Planned Next Dose (Ctrough) | Tarlatamab Dose Expansion | 5.36 | Geometric Coefficient of Variation 36 | μg/mL | |
| Area Under the Concentration-time Curve Over the Dosing Interval From Time 0 to 336 Hours (AUC336) of Tarlatamab | Tarlatamab Dose Expansion | Cycle 2 Day 1 | 4010 | Geometric Coefficient of Variation 28 | hr*μg/mL |
| Area Under the Concentration-time Curve Over the Dosing Interval From Time 0 to 336 Hours (AUC336) of Tarlatamab | Tarlatamab Dose Expansion | Cycle 2 Day 15 | 4260 | Geometric Coefficient of Variation 26 | hr*μg/mL |
| Terminal Phase Elimination Half-life (t1/2,z) of Tarlatamab | Tarlatamab Dose Expansion | 7.23 | Geometric Coefficient of Variation 33 | days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04702737/results